RW

Reno Winter

Chief Technical Officer

Egle Therapeutics

Munich, Bavaria


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
Egle Therapeutics
Industry
research
Employees
45.0
Seniority
C suite
Annual Revenue
1800000.0
Total Funding
56676022.0
Latest Funding
Other

Technologies

Outlook Microsoft Office 365 Mobile Friendly Google Font API reCAPTCHA Bootstrap Framework WordPress.org Google Tag Manager Basis AI

Keywords

biotechnology research regulatory t cells treg modulation immunotherapy cancer treatment autoimmune disease il-2 cytokine variants immune response antibody therapeutics treg-specific targets clinical-stage biotechnology innovative drug candidates egl-001 egl-003 treg-targeted therapies tumor microenvironment immune checkpoint blockade drug development clinical trials preclinical studies fcell treg engagement anti-ctla4 tumor-associated tregs immune suppressor solid tumors therapeutic efficacy t cell activation drug candidates novel treg targets antibody fusion proteins biotechnology company transformative therapies investor relations scientific leadership clinical development patient care bioinformatics combinational therapy personalized medicine therapeutic pipeline treg activation suppressive immune cells multifunctional therapies live biotherapeutics advanced cancer care early-stage biotechnology precision medicine therapeutic innovation biotech industry patient-centric treatments biomedical research health care health wellness & fitness hospital & health care information technology & services biotechnology

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans